A New Drug From Sea Sponge For The Treatment Of Severe Breast Cancer

A New Drug From Sea Sponge For The Treatment Of Severe Breast Cancer.
A additional chemotherapy tranquillizer made from a pond sponge extended the lives of women with metastatic breast cancer by about 2,5 months, researchers report. The encouraging finding on the drug, known as eribulin, was presented Sunday at the annual get-together of the American Society of Clinical Oncology in Chicago. "We have a major need for unknown therapies," noted study author Dr Christopher Twelves herbaltor men. "We see a statistically significant promote in overall survival in a situation where we rarely see this sort of improvement".

So "Eribulin targets the mechanisms by which the cells divide, which is several from previous agents," explained Twelves, who is a professor of clinical cancer pharmacology and oncology and conduct of the Clinical Cancer Research Groups at the Leeds Institute of Molecular Medicine and St James' Institute of Oncology in Leeds, UK. More than 750 women were randomized to experience either eribulin or a "treatment of physician's choice," the survive because there isn't a standard therapy for this type of cancer naturomax. In almost all cases, it was another chemotherapy.

The study included women who had already been treated extensively for their cancer, with the customary patient already having undergone four chemotherapies. The researchers appear a 23 percent improvement in median survival when women took eribulin, with the median survival for those in the eribulin body at just over 13 months vs 10,7 months in the treatment-of -choice group. "These results potentially seat eribulin as a new and effective treatment for women with heavily pretreated knocker cancer," said Twelves, who disclosed financial ties with Eisai, which makes eribulin.

Also featured at the convocation Sunday, Italian researchers report that liver biopsies can disclose whether a breast cancer that has spread through the body has changed its cellular characteristics, such as estrogen-receptor status, progesterone-receptor station or HER2 status. These tumor properties often dictate the type of treatment a woman receives, spirit that some women may benefit from switching therapy if the characteristics of their cancer change.